MERLIN THERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 30 Jan 2026)
What this means for you
Not registered yet, but its 05 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97488797
- Mark type
- Design + words
- Filed
- 05 Jul 2022
- Published for opposition
- 04 Jun 2024
- Attorney of record
- Cheryl A. Clarkin, Esq.
Goods and services
- Class 042 — Scientific and technological services: research and development for the treatment or cure of the rare genetic disorder Neurofibromatosis Type 2; conducting clinical trials for others for the treatment of Neurofibromatosis Type 2
Owner
- Merlin Therapeutics, Inc., West Chester, PA, US
- Merlin Therapeutics, Inc., West Chester, PA, US
Prosecution history
- 31 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Jan 2026 — SOU EXTENSION 3 GRANTED
- 30 Jan 2026 — SOU EXTENSION 3 FILED
- 30 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jul 2025 — SOU EXTENSION 2 GRANTED
- 14 Jul 2025 — SOU EXTENSION 2 FILED
- 14 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Jan 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2025 — SOU EXTENSION 1 GRANTED
- 27 Jan 2025 — SOU EXTENSION 1 FILED
- 27 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 30 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jun 2024 — PUBLISHED FOR OPPOSITION